GLP-1 drugs show promise for binge eating disorder: what Canadian patients should know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

A July 2026 review published in the BMJ, described by its authors as the largest synthesis of evidence to date, found that GLP-1 (glucagon-like peptide-1) receptor agonist medications may reduce symptoms of binge eating disorder (BED), especially in patients who also live with obesity. For Canadians, the finding matters because semaglutide (sold in Canada as Ozempic for type 2 diabetes and Wegovy for chronic weight management) and liraglutide (sold as Saxenda) are already prescribed in this country, but Health Canada has not approved any GLP-1 drug specifically for binge eating disorder, meaning off-label use and coverage gaps are the current reality for most patients.

Binge eating disorder is defined as recurrent episodes of eating a large amount of food in a short period while feeling a loss of control, without the compensatory behaviours seen in bulimia nervosa. It affects an estimated 17 million people worldwide, according to the BMJ review, and roughly two thirds of those individuals live with overweight or obesity. In Canada, BED is the most common eating disorder by prevalence, yet it remains underdiagnosed and underfunded relative to anorexia and bulimia in provincial mental health systems.

What this means in Canada

Health Canada has approved semaglutide (Wegovy) and liraglutide (Saxenda) for chronic weight management in adults with a body mass index of 30 or above, or 27 or above with at least one weight-related condition. Neither drug carries a Health Canada indication for binge eating disorder. The only medication currently approved in Canada specifically for BED is lisdexamfetamine (Vyvanse), a stimulant that carries its own contraindications and is not appropriate for all patients.

Provincial pharmacare coverage for GLP-1 drugs in Canada is inconsistent. Ontario's OHIP does not cover Wegovy or Saxenda for weight management alone; coverage through the Ontario Drug Benefit program is limited to patients with specific metabolic conditions. Quebec's RAMQ similarly restricts GLP-1 coverage to diabetes indications in most cases. British Columbia's PharmaCare and Alberta's AHCIP have comparable restrictions. Patients seeking these drugs for BED-related reasons would, in most provinces, pay out of pocket, with Wegovy running approximately $400 to $500 CAD per month without insurance.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a position statement on GLP-1 drugs and eating disorders. The Canadian Psychiatric Association and the National Eating Disorder Information Centre (NEDIC) have not yet published formal guidance on GLP-1 use in BED as of this article's publication date.

Canadian telehealth platforms including Felix, Maple, and Cleo, as well as Science & Humans (scienceandhumans.com), offer GLP-1 prescribing for weight management, but none advertise BED-specific protocols. US-only platforms such as Midi, Hone Health, and Winona do not serve Canadian patients.

What changed

The BMJ review is significant not because it settles the question but because it consolidates a scattered body of small trials and case series into one analysis. Senior author Ilaria Costantini, a research fellow in psychiatric epidemiology at the UCL Division of Psychiatry, told the BMJ that GLP-1 drugs may help some individuals with BED develop a healthier relationship with food, while cautioning that for others the drugs could reinforce rigid eating patterns.

The biological rationale is plausible. GLP-1 receptor agonists slow gastric emptying, reduce appetite, and appear to dampen the reward signalling associated with highly palatable foods. Researchers have hypothesised that this dampening effect could interrupt the compulsive eating cycle in BED. However, the review's authors were explicit that the evidence base remains limited, with most included studies being small, short in duration, and not designed primarily to measure eating disorder outcomes.

This is not the first time a drug developed for one purpose has been examined for BED. Lisdexamfetamine (Vyvanse) received its BED indication in the US (FDA-approved) and in Canada (Health Canada-approved) after randomised controlled trials showed it reduced binge episodes. The GLP-1 evidence is at an earlier stage than Vyvanse's was at approval.

What Canadian patients should know

If you have been diagnosed with binge eating disorder and are also managing obesity, it is reasonable to ask your physician or psychiatrist whether a GLP-1 drug might be appropriate for your situation. That conversation should include your full medical history, any history of eating disorder behaviours, cardiovascular status, and whether you have a concurrent diagnosis that might qualify you for covered GLP-1 access under your provincial formulary.

Patients should be aware that GLP-1 drugs are not appetite suppressants in the simple sense. Clinicians working in eating disorder settings have raised concerns that the appetite-suppressing effects of these drugs could, in some patients, reinforce restrictive patterns or mask hunger cues that are part of recovery work. The BMJ review's authors acknowledged this tension directly.

If cost is a barrier, some private insurers in Canada cover GLP-1 drugs for weight management under group benefit plans. Manufacturer patient-support programs (Novo Nordisk's Wegovy patient support program, for example) may offer partial assistance, though eligibility criteria apply. Patients in Ontario can also apply for the Exceptional Access Program if a clinician can document medical necessity.

For eating disorder support in Canada, the National Eating Disorder Information Centre (NEDIC) operates a helpline at 1-866-NEDIC-20 and provides referrals to provincially funded treatment programs.

Limitations and open questions

The BMJ review does not establish that GLP-1 drugs are effective treatments for binge eating disorder. The included studies were heterogeneous, mostly small, and not powered to detect changes in BED-specific diagnostic criteria. No randomised controlled trial has yet been designed with BED remission as a primary endpoint for a GLP-1 drug.

Health Canada has not issued guidance on GLP-1 use in eating disorders, and the SOGC has not weighed in. It is not known whether the symptom reductions seen in the reviewed studies translate to long-term recovery, reduced psychological distress, or improved quality of life. The question of whether GLP-1 drugs interact with existing BED treatments, including cognitive behavioural therapy and lisdexamfetamine, has not been studied in any rigorous way.

Larger, longer trials with eating disorder specialists involved in study design are needed before any clinical society or regulator is likely to update prescribing guidance. Until then, any use of GLP-1 drugs for BED in Canada remains off-label and should involve a multidisciplinary team that includes mental health support.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.